CSTL: overvalued.
Figures as of the 2026-09-22 close.
Castle Biosciences Inc carries debt worth 0.08 times its shareholders' equity, a light load. Its current assets cover its short-term liabilities 6.04 times.
Its Altman Z-Score, computed from its latest annual report, falls in the safe zone: its accounts do not show the pattern that has preceded bankruptcies. It is a statistical warning light, not a forecast.
It scores 3 out of 9 on the Piotroski F-Score, which checks whether profitability, leverage and efficiency improved from one annual report to the next. Seven or more is strong; three or fewer is weak. Which tests it passes, and the red flags in its accounts, are in the full analysis.